- Fitch Ratings assigns underlying 'A+' to
airport system revenue bonds for the...
AIRLINE INDUSTRY INFORMATION-(C)1997-2007 M2 COMMUNICATIONS LTD Fitch Ratings has assigned an underlying 'A+' rating to approximately USD356.5m City and County of Denver, Colorado, series ......
- Fitch Ratings affirms rating on Connecticut airport
revenue bonds.
AIRLINE INDUSTRY INFORMATION-(C)1997-2007 M2 COMMUNICATIONS LTD Fitch Ratings has affirmed the underlying 'A' rating on the State of Connecticut's general airport revenue bonds. The ......
- Fitch Upgrades PG&E IDR to 'BBB+'; Outlook Positive.
NEW YORK -- Fitch Ratings has upgraded Pacific Gas and Electric Company (PG&E) as follows: --Issuer Default Rating (IDR) to 'BBB+' from 'BBB'; --senior unsecured ......
- Taro Announces `AA' Bond Rating In
Israel.
Business Editors HAWTHORNE, N.Y.--(BUSINESS WIRE)--March 31, 2003 Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS:TARO) today announced that it has received an "AA" rating from Maalot, the Israeli ......
- Taro Expects to Complete 2005 Audit in
August.
HAWTHORNE, N.Y. -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company," NASDAQ: TARO) today announced that it is in the last stages of completing the ......
- Taro and J.B. Chemicals to Collaborate on Product
Development for U.S. and Other Markets.
HAWTHORNE, N.Y. -- Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO, the "Company") reported today that it has entered into agreements with J.B. Chemicals & Pharmaceuticals ......
- Dreaming of taro.
Kalo (taro), the staff of life for Polynesians, has proven to be remarkably versatile and adaptive to modern needs and tastes. Taro-based products have included ......
- Report to Taro from Independent Counsel Delayed, Expected by October 27, 2006.
HAWTHORNE, N.Y. -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company," NASDAQ: TARO) today announced that a report from independent counsel relating to the previously announced ......
- Taro Provides Update on Filing of 2005 Form
20-F.
HAWTHORNE, N.Y. -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company," NASDAQ: TARO) today provided an update on the Company's progress in filing its Annual ......
- Taro Expects to Receive Report from Independent Counsel by October 20, 2006.
HAWTHORNE, N.Y. -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company," NASDAQ: TARO) today announced that its Board of Directors presently expects to receive the report ......
- Taro Announces Filing Of ANDA For Oxcarbazepine
Tablets 150, 300 And 600 MG.
HAWTHORNE, N.Y. -- Taro Pharmaceutical Industries Ltd. ("Taro," NASDAQ: TARO) today reported that it has filed an Abbreviated New Drug Application ("ANDA") with the ......
- Taro Pharmaceuticals Announces ``A'' BondRating in Israel; Rating Provided by Maalot,...
HAWTHORNE, N.Y.--(BUSINESS WIRE)--May 18, 1999-- Taro Pharmaceutical Industries Ltd. (Nasdaq:TAROF) today announced that it received an "A" rating, according to the standards employed in Israel, ......
- Taro Receives Approval for Hydrocortisone Butyrate
Cream USP, 0.1% ANDA; Generic...
HAWTHORNE, N.Y. -- Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) reported today that it has received approval from the U.S. Food and Drug Administration for ......
- Taro Receives Nasdaq Notice of Possible Delisting for
Delayed Filing of 2005 Form 20-F.
HAWTHORNE, N.Y. -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company," NASDAQ: TARO) reported today that on July 19, 2006 it received a Staff Determination ......
- Taro Receives Approval for Terconazole Vaginal Cream,
0.4% ANDA; Generic Equivalent to...
HAWTHORNE, N.Y. -- Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) and its affiliates and subsidiaries ("Taro") reported today that it has received approval from the ......